FDA Narrows Fluoride Supplement Recommendations for Children Amid Safety Review

WASHINGTON — The U.S. Food and Drug Administration on Friday, Oct. 31, 2025, issued new limits on pediatric fluoride supplements, advising that the products should no longer be used in children younger than 3 years and should be reserved for older children only when they face a pronounced risk of tooth decay. The decision marks the most recent policy step by Health Secretary Robert F. Kennedy Jr. and senior agency officials targeting the longstanding role of fluoride in dental care.

The updated guidance departs from prior practice that allowed prescriptions for infants as young as six months. Instead of ordering an immediate market withdrawal — an action the agency publicly contemplated in May — regulators sent warning letters to four manufacturers directing them to curb distribution and marketing outside the new parameters.

Fluoride tablets and lozenges are periodically recommended for children and adolescents who live in areas with low levels of naturally occurring or added fluoride in municipal water systems. Pharmaceutical drops formulated for babies are also available. Under the revised policy, these products should be considered only for patients with demonstrated elevated susceptibility to cavities, the FDA said.

Alongside the enforcement notices, the agency released a comprehensive scientific review concluding that the preventive benefits of the supplements appear limited and may be offset by emerging safety signals. Investigators cited potential links to gastrointestinal effects, weight gain, and possible cognitive impacts. The analysis also highlighted evidence that fluoride’s antibacterial action in the mouth could similarly alter gut bacteria, raising broader health questions.

In a separate bulletin, the FDA circulated a form letter to dentists, pediatricians, and other health professionals outlining the newly identified risks and advising careful patient selection before prescribing the supplements.

The American Dental Association (ADA) has publicly disputed assertions of systemic harm at dentist-recommended exposure levels, characterizing fluoride as safe and effective when used appropriately. Nevertheless, the organization acknowledges that supplemental fluoride can cause dental fluorosis — a mottling or discoloration of tooth enamel — if total intake exceeds optimal levels. The FDA review noted this cosmetic side effect while emphasizing the additional systemic concerns under examination.

Some dental practitioners warn that restricting access could lead to higher rates of cavities in rural or underserved communities, where centralized water fluoridation is less common. Secretary Kennedy has separately announced plans to phase out the addition of fluoride to public water supplies nationwide, a move that would represent a significant shift from current public health policy.

Imagem: financial planning 51

Community water fluoridation has been endorsed for decades by major health bodies. The Centers for Disease Control and Prevention states that fluoride strengthens tooth enamel by replacing minerals lost during routine wear and reduces cavity prevalence across populations. In 1962, federal officials established recommended fluoride concentrations for municipal water, guidelines still referenced by local utilities.

Under federal law, the FDA oversees the safety and labeling of over-the-counter and prescription dental products, including fluoride-containing toothpastes, mouth rinses, and professional treatments offered in dental offices. Friday’s action does not affect those products or adult use; it applies only to orally ingested supplements intended for children.

Kennedy, a former environmental attorney appointed to lead the Department of Health and Human Services, has characterized fluoride as a neurotoxin associated with multiple health hazards. His tenure has included several reviews of chemicals long considered staples of preventive medicine. The supplement directive continues that pattern, although the agency opted for a limited restriction rather than an outright ban at this stage.

Manufacturers that received the warning letters have 15 days to inform the FDA of corrective steps. Regulators indicated they will monitor compliance and evaluate additional data as it becomes available. For now, health providers are instructed to weigh cavity risk, water-fluoride content, and patient age before recommending any fluoride supplement.

Crédito da imagem: Associated Press